ONCOSOFT (CEO Kim Jin sung), a medical AI (artificial intelligence) company, announced today that it officially entered the Japanese market through the recent Japan Society of Radiation Oncology 2024 (JASTRO 2024). The company's AI contouring technology won second place in the AI contouring competition 'ADAPT' organized by the conference.
The competition evaluates AI technology for automatic contouring of normal organs for radiation treatment planning. ONCOSOFT's AI solution, OncoStudio,was highly recognized for its accuracy and speed in the head and neck region.
In addition to receiving the award, ONCOSOFT also gave a lecture on the company's technology during the conference. Dr. Lee Jong-min,head of ONCOSOFT's AI research team, shared OncoStudio's core technology and clinical use cases.
“This conference was an opportunity to officially introduce our company to Japan.” said Kim Jin sung, CEO of ONCOSOFT, ”and we also achieved good results in the global competition.” “As OncoStudio's performance and potential have been objectively recognized, we will continue to make good progress in the global market.”
In October, ONCOSOFT signed an exclusive sales agreement with Japanese medical device company Anzai Medical to distribute OncoStudio in Japan. ONCOSOFT plans to launch the product in the Japanese market in 2025.
Meanwhile, JASTRO 2024 was recently held in Yokohama, Japan, at the 37th Japanese Society of Radiation Oncology, an academic event that shares the latest technologies and research trends in the field of radiation therapy in Asia.
